ArticleBMC pediatrics2025
Analysis of antimicrobial resistance and clinical features of Staphylococcus aureus-infected bone and joint infections in children.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Developing a nomogram based on admission AGR and CLR to predict subsequent surgical intervention in pediatric acute hematogenous osteomyelitis.Scientific reports · 2026Article
- Repurposing Azeliragon as a novel antibacterial agent against methicillin-resistant Staphylococcus aureus via combined membrane phospholipids and cell wall targeting.Communications biology · 2026Article
- A model for predicting the likelihood of negative culture results in children with osteoarticular infections.European journal of medical research · 2026Article
- Sex, age, and seasonal distribution characteristics of bacterial and fungal infections.PloS one · 2026Article
- Predictive value of AFR and UCR for the methicillin-resistant Staphylococcus aureus infection in children with bone and joint infection.Scientific reports · 2025Article
- Study of the release kinetics of dalbavancin from bone allografts.Journal of materials science. Materials in medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
objectiveThis study investigates the antimicrobial resistance and clinical features of Staphylococcus aureus (S. aureus) in bone and joint infections (BJIs) among children under 14 years old, providing insights for optimal antibiotic usage.
methodsA retrospective analysis was conducted on the clinical data from children treated for BJIs at the Children's Hospital of Soochow University between January 2019 to December 2023. Bacterial cultures were examined, focusing on S. aureus. Clinical features of children with methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant Staphylococcus aureus (MRSA) infections were compared.
resultsAmong the 110 cases of culture-positive BJIs, 116 pathogenic strains were identified, with, S. aureus being the most prevalent (75.00%, 87/116). No resistance to quinupristin/dalfopristin, linezolid, vancomycin, tigecycline, rifampin or teicoplanin was detected. The resistance rate to penicillin was 90.80% (79/87), while resistance rates to clindamycin and erythromycin were 37.93% (33/87) and 36.78% (32/87), respectively. MRSA accounted for 28.74% (25/87) of S. aureus isolates. There were no significant differences in gender, age, infection site, clinical symptoms, laboratory indicators, hospital stay, or surgical intervention between MSSA and MRSA groups (p > 0.05). However, patients with positive X-ray findings were more likely to have MRSA infections (p = 0.033). Subgroup analysis revealed that children older than 48 months with positive X-ray results were more likely to have MRSA (p = 0.048).
conclusionIn China, S. aureus remains the predominant pathogen in children under 14 years old with BJIs. Among children older than 48 months, nearly one-third of BJIs are caused by MRSA, and positive X-ray findings may indicate a higher likelihood of MRSA in this age group. Further studies are required to validate these findings before they can be widely applied. CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.